NEW YORK (GenomeWeb News) – GNS Healthcare today announced a deal to use clinical and molecular information from Bristol-Myers Squibb aimed at immuno-inflammation.
The goal of the collaboration is to discover new biomarkers and uncover new disease biology.
GNS will use its reverse-engineering and forward-simulation, or REFS, platform and data from Bristol-Myers Squibb to build computer models, "in a hypothesis-free, unbiased manner that will be simulated to identify key molecular mechanisms," the Cambridge, Mass.-based company said.
The computer models will serve to support virtual clinical trials that simulate the clinical effect of inhibiting various drug targets and to help identify new molecular targets for specific types of patients.
Data from the drug manufacturer will include genetic information, gene expression levels, specific blood markers, and clinical outcomes.
"This is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes," Iya Khalil, executive vice president and co-founder of GNS, said in a statement.
Financial and other terms of the collaboration were not disclosed.